OP007 Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn's disease patients who are anti-TNF inadequate responders: Results from the TOSCA study
G. D’Haens(Radboud University Nijmegen), Walter Reinisch(Medical University of Vienna), Séverine Vermeire(KU Leuven), R. M. Ransohoff(Radboud University Nijmegen), Bingjie Jin(Radboud University Nijmegen), William J. Sandborn(University of San Diego), Olaf Stüve(Southwestern Medical Center), Fabio Cataldi(Pfizer (United States)), Gail M. Comer(Pfizer (United States)), Matthieu Allez(Inserm), M. Hassan-Zahraee, Artur Kamiński, Bo Jin(Radboud University Nijmegen), Sunday Rivers(Pfizer (United States)), Pierre Desreumaux(Active Biotech (Sweden)), Ken Gorelick(Pfizer (United States)), H Vogelsang(Radboud University Nijmegen), Vivek Pradhan(Pfizer (United States)), A. Van Gossum(Université Libre de Bruxelles), DC Baumgart(Radboud University Nijmegen), John Cheng(Pfizer (United States))
Cited by 11
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Crohn's disease
|The Lancet|2012|2.1k